Table 1.
Demographics and further clinical details of MDRO-colonized HCT recipients.
| Characteristic | FMT MDRO (n = 8) | No FMT MDRO (n = 11) | P |
|---|---|---|---|
| Patient age (years) | |||
| (Median, range) | 61.9 (33-70) | 59.8 (31-66) | 0.32 |
| Diagnosis to HCT (years) | |||
| (Median, range) | 0.8 (0.3-9.6) | 0.5 (0.3-13.3) | 0.89 |
| Disease | |||
| CML | 2 (25%) | 2 (18%) | 0.68 |
| AML/MDS | 3 (38%) | 7 (64%) | |
| ALL | 2 (25%) | 1 (9%) | |
| T-cell lymphoma | 1 (13%) | 1 (9%) | |
| Disease Risk Index (EBMT) | |||
| Low | 4 (50%) | 7 (64%) | 0.89 |
| Intermediate | 4 (50%) | 2 (18%) | |
| High | 0 | 2 (18%) | |
| Karnofsky score at HCT | |||
| <=80% | 3 (38%) | 2 (18%) | 0.27 |
| 90% | 3 (38%) | 3 (27%) | |
| 100% | 2 (25%) | 6 (55%) | |
| Donor type | |||
| Matched sibling | 3 (38%) | 4 (36%) | 0.71 |
| Matched unrelated | 4 (50%) | 4 (36%) | |
| Haploidentical | 1 (12%) | 3 (27%) | |
| Conditioning | |||
| Reduced intensity | 7 (88%) | 7 (64%) | 0.34 |
| Myeloablative | 1 (13%) | 4 (36%) | |
| Patient - Donor sex match | |||
| Female into male | 1 (13%) | 2 (18%) | 1.00 |
| Other | 7 (88%) | 9 (82%) | |
| CMV donor/recipient | |||
| negative to negative | 2 (25%) | 2 (18%) | 0.62 |
| positive to negative | 0 | 1 (9%) | |
| negative to positive | 3 (38%) | 2 (18%) | |
| positive to positive | 3 (38%) | 6 (55%) | |
| HCT - comorbidity index | |||
| 0 | 1 (13%) | 3 (27%) | 0.45 |
| 1 or 2 | 4 (50%) | 4 (36%) | |
| >=3 | 3 (37%) | 4 (36%) | |
| Year of HCT | |||
| <2018 | 3 (38%) | 7 (64%) | 0.37 |
| >2017 | 5 (62%) | 4 (36%) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; EBMT, European Society for Blood and Marrow transplantation; FMT, fecal microbiota transplant; HCT hematopoietic cell transplantation; MDS, myelodysplastic syndrome; MDRO, Multidrug-resistant organisms.